TA1 vs Thymosin Alpha-1
A side-by-side research comparison of TA1 and Thymosin Alpha-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Thymosin Alpha-1 |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Thymosin Alpha-1 (Thymalfasin) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Approved internationally (not FDA-approved) |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles. |
| Molecular weight | 3108.3 Da | 3108.3 Da |
| Half-life | ~2-3 hours | ~2-3 hours |
| Bioavailability | ~85% subcutaneous | ~85% subcutaneous |
| Typical dose | 1.6 mg | 1.6-3.2 mg |
| Frequency | 2x per week | 2-3x per week |
| Route | Subcutaneous injection | Subcutaneous injection |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Thymosin Alpha-1 reported benefits
- Enhanced T-cell immunity
- Anti-viral activity
- Dendritic cell activation
- Cancer immunosurveillance
- Vaccine adjuvant effects
Related comparisons
Research and educational reference only. Not medical advice.